|
US2019022129A1
|
|
Beta-glucan immunotherapies affecting the immune microenvironment
|
|
CN107106593A
|
|
Influence the beta glucan method and composition of tumor microenvironment
|
|
EP3166616A1
|
|
Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
|
|
US2017027210A1
|
|
Yeast cell wall enriched in mannan oligosaccharide protein
|
|
MX2016007148A
|
|
A-glucan assay methods.
|
|
CN106133130A
|
|
Reduce the method that the abnormal flavour of glucosan produces
|
|
AU2014201427A1
|
|
Glucan preparations
|
|
CN104812243A
|
|
Compositions and methods for beta-glucan immunotherapy
|
|
EP3354319A1
|
|
Compositions including beta-glucans and methods of use
|
|
WO2012167061A1
|
|
OPSONIZED β-GLUCAN PREPARATIONS AND METHODS
|
|
WO2012154818A1
|
|
B-glucan compounds, compositions, and methods
|
|
WO2012154680A2
|
|
MODIFIED AND DERIVATIZED β-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS
|
|
EP2461870A1
|
|
Composition comprising beta-glucan and an egf-r antibody or an egf-r antagonist for use in the treatment of kras-mutated tumors
|
|
AU2008305545A1
|
|
Beta-glucan treatment of upper respiratory tract infection symptoms and psychological well-being
|
|
AU2007258191A1
|
|
Glucan preparations
|
